에 대한 최신 뉴스 Geovax Labs (NASDAQ:GOVX) 주식

Geovax Labs

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Broad U.S. Equity ETFs

Tech

ETFs

APDN

ASTS

CING

CRWD

INDO

SERV

VRAX

ZAPP

매일의 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.

단독: 2024년 8월 벤징가 프로에서 가장 검색량이 많았던 상위 20개 티커는?

Biotech

News

Health Care

After-Hours Center

Movers

지오백스 랩스(NASDAQ:GOVX)의 주가는 수요일 뉴욕 시장 마감을 앞두고 급등했고, 미시간주 웨인(Wayne) 카운티에서 2022년 이후 첫 번째 엠폭스(mpox, 원숭이두창) 사례가 확인됐다는 보도가 나온 후 시간외 거래에서 계속해서 반등했다.

지오백스의 주식, 수요일 시장 마감 직전부터 시간외 거래까지 급등 지속: 무슨 일이?

Geovax Labs Inc

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

General

AEMD

CMRX

MRNA

TNXP

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

<a href="https://geovax.com/investors/press-releases/geovax-advanced-mva-manufacturing-process-aimed-to-enhance-vaccine-supply-worldwide">https://geovax.com/investors/press-releases/geovax-advanced-mva-manufacturing-process-aimed-to-enhance-vaccine-supply-worldwide</a>
Process Expected to Increase Production Yield, Flexibility at Lower Cost
Atlanta, GA – January 27, 2025 – GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has shared updates about its development-stage advanced Modified Vaccinia Ankara (MVA) vaccine manufacturing process. This anticipated process provides the potential to not only address today's pressing health challenges but also paves the way for more efficient, flexible and lower-cost MVA-vaccine manufacturing.
The Power and Versatility of the MVA Platform
The MVA platform is uniquely designed to incorporate multiple antigens into a single vaccine. This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine, the MVA platform offers distinct advantages, including:
<ul>
<li>Protection against diseases such as Mpox and smallpox.</li>
<li>Multi-antigen vaccines like GEO-CM04S1, which targets both the Spike (S) and Nucleocapsid (N) antigens of SARS-CoV-2.</li>
<li>Stability under minimal refrigeration and the potential for freeze-drying (lyophilization), simplifying distribution in resource-limited settings.</li>
</ul>
Advancing MVA Manufacturing
Current vaccine manufacturing methods rely on Chicken Embryo Fibroblast (CEF) cells, requiring pathogen-free eggs. This process is costly, time-consuming, and dependent on limited egg supplies, providing barriers to rapid, real-time MVA manufacturing, as well as hindering the flexibility necessary to establish local MVA manufacturing of critically important vaccines. &nbsp;GeoVax is addressing these barriers through an advanced MVA Manufacturing process utilizing an avian cell line licensed from ProBioGen AG (Berlin). Key features include:
<ul>
<li>A continuous avian suspension cell line process that eliminates the need for pathogen-free eggs.</li>
<li>Compatibility with standard manufacturing equipment, reducing setup time, simplifying the MVA manufacturing process, increasing scalability and lowering manufacturing costs.</li>
</ul>
This advanced MVA manufacturing process is expected to significantly simplify vaccine production, particularly in middle- and low-income regions where supply chain issues often hinder access to critical vaccines.
Addressing Global Health Needs
"Our advanced MVA manufacturing process represents not only a transformative manufacturing advance but also addresses a public health imperative," said David Dodd, Chairman and CEO of GeoVax. "By tackling disease protection, logistical hurdles, and manufacturing challenges, we aim to empower regions like Africa with the tools needed to combat current and future health crises."
GeoVax's MVA vaccines have demonstrated robust performance in clinical trials, with ongoing Phase 2 studies for GEO-CM04S1, its COVID-19 vaccine candidate, showing broad and durable immune responses. Supported by its BARDA Project NextGen Award and partnerships with leading manufacturing and development organizations, GeoVax is positioned to enhance vaccine access and delivery on a global scale.
Recent Conference Presentations
GeoVax CEO David Dodd recently presented the company's strategic initiatives and the potential of GEO-MVA at:
<ul>
<li>Biotech Showcase: January 14, 2025</li>
<li>Emerging Growth Conference: January 16, 2025</li>
</ul>

GeoVax Shares Update On Its Advanced MVA Manufacturing Process, Aimed To Enhance Vaccine Supply Worldwide

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $18 price target.

Price Target

Analyst Ratings

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target

<a href="https://geovax.com/investors/press-releases/geovax-announces-major-gedeptin-milestone-with-plans-of-phase-2-trial" title="https://geovax.com/investors/press-releases/geovax-announces-major-gedeptin-milestone-with-plans-of-phase-2-trial">https://geovax.com/investors/press-releases/geovax-announces-major-gedeptin-milestone-with-plans-of-phase-2-trial</a>

GeoVax Announces Major Gedeptin Milestone With Plans Of Phase 2 Trial

GeoVax Receives Notice Of Allowance For Patent Application Titled 'Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.'

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

GOVXW

GeoVax Reports Interim Data For Phase 2 Trial Of COVID-19 Booster Vaccine GEO-CM04S1 In CLL Patients; DSMB Recommends Continued Enrollment As GEO-CM04S1 Outperforms mRNA Vaccine In Immune Response Evaluation

GeoVax Labs Received Notice From Nasdaq Notifying The Company That, Co. Complies With Stockholders' Equity Listing Rule

<h3>Gainers</h3>
<ul>
<li>Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) shares rose 22.7% to $2.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $331.2 million. As per the news, the Q3 earnings report came out today. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 19.74% to $2.46. The market value of their outstanding shares is at $31.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 18.48% to $2.5. The market value of their outstanding shares is at $29.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) shares rose 16.66% to $157.64. The company's market cap stands at $19.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 15.62% to $0.78. The market value of their outstanding shares is at $11.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) stock increased by 12.61% to $8.66. The company's market cap stands at $286.3 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares decreased by 85.6% to $0.39 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.5 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock decreased by 72.24% to $0.44. The market value of their outstanding shares is at $2.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock fell 23.4% to $0.05. The company's market cap stands at $2.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares declined by 20.03% to $0.21. The market value of their outstanding shares is at $32.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares declined by 20.0% to $2.6. The company's market cap stands at $22.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 17.6% to $0.51. The market value of their outstanding shares is at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

CLDI

ENSC

GCTK

KAPA

LXEO

MRSN

NTRA

SYRS

VRPX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

GeoVax Labs shares are trading lower. The company reported Q3 financial results.

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.48) by 38.51 percent. The company reported quarterly sales of $2.789 million which beat the analyst consensus estimate of $918.750 thousand by 203.56 percent.

Earnings

Earnings Beats

Geovax Labs Q3 2024 GAAP EPS $(0.91) Beats $(1.48) Estimate, Sales $2.789M Beat $918.750K Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad9359b85e930001f9718e/jason-wittes">Roth MKM analyst Jason Wittes </a>initiated coverage on TriSalus Life Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) with a Buy rating and announced a price target of $11. TriSalus Life Sciences shares closed at $4.23 on Friday. <a href="https://www.benzinga.com/quote/TLSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/606af1536538960001bced45/james-molloy">Alliance Global Partners analyst James Molloy</a> initiated coverage on GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy rating and announced a price target of $15. Geovax Labs shares closed at $1.95 on Friday. <a href="https://www.benzinga.com/quote/GOVX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GOVX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-1024x574.png" alt="" class="wp-image-640412" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/11081824/image-110.png 1198w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41871463/dow-sp-500-notch-best-week-of-year-as-tesla-surges-post-trump-win-investor-sentiment-improves-fear-greed-index-remains-in-neutral-zone">Dow, S&amp;P 500 Notch Best Week Of Year As Tesla Surges Post Trump Win: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

MRCY

TLSI

UEIC

This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Geovax Labs to report an earnings per share (EPS) of $-1.48.
The market awaits Geovax Labs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $2.44, leading to a 1.11% drop in the share price on the subsequent day.
Here's a look at Geovax Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-4.43</td>
<td>-3.15</td>
<td>-2.78</td>
<td>-3.6</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.99</td>
<td>-2.47</td>
<td>-3.94</td>
<td>-4.8</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731344529_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Geovax Labs were trading at $1.95 as of November 08. Over the last 52-week period, shares are down 72.81%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GOVX/earnings">To track all earnings releases for Geovax Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Geovax Labs

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of $10.00. The ...

Noble Financial Keeps Their Buy Rating on GeoVax Labs (GOVX)

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on GeoVax Labs (GOVX – Research Report). The associated price target ...

GeoVax Labs: Promising Developments in COVID-19 Vaccine and Therapeutics Propel Buy Rating

First mpox case linked to African outbreak reported in U.S.

GeoVax Labs (GOVX) announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical t...

GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of $12.00. The ...

GeoVax Labs (GOVX) Receives a Buy from Noble Financial

The World Health Organizatiton said that Director-General Dr. Tedros Adhanom Ghebreyesus, agreeing with the advice of the IHR Emergency Committee, ...

WHO determines mpox upsurge still constitutes public health emergency

GeoVax Labs (GOVX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to Ge...

GeoVax Labs receives Notice of Allowance for cancer vaccine patent

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on GeoVax Labs (GOVX – Research Report), with a price targe...

Noble Financial Remains a Buy on GeoVax Labs (GOVX)

In crowded Kinshasa, the capital of the Democratic Republic of Congo, two strains of mpox are sweeping through a community that relies on selling s...

Mpox spreading in Congo's capital, NY Times reports

GeoVax Labs (GOVX) announced significant progress in advancing Gedeptin as a cancer therapy. Gedeptin, based on a Gene-Directed Enzyme Prodrug Ther...

Comments

Geovax Labs

뉴스

에 대한 최신 뉴스 Geovax Labs (NASDAQ:GOVX) 주식

수요일, 10월 02, 2024

수요일, 9월 04, 2024

수요일, 8월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌